EP2731603A1 - Stable dosage forms of arterolane and piperaquine - Google Patents

Stable dosage forms of arterolane and piperaquine

Info

Publication number
EP2731603A1
EP2731603A1 EP12743776.2A EP12743776A EP2731603A1 EP 2731603 A1 EP2731603 A1 EP 2731603A1 EP 12743776 A EP12743776 A EP 12743776A EP 2731603 A1 EP2731603 A1 EP 2731603A1
Authority
EP
European Patent Office
Prior art keywords
dosage form
active compound
piperaquine
solid oral
stable solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12743776.2A
Other languages
German (de)
English (en)
French (fr)
Inventor
Arno Appavoo Enose
Harish Kumar Madan
Sumit Madan
Anupam Trehan
Puneet Tyagi
Vinod Kumar Arora
Sanjukta Bhattacharyya
Arjun Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/183,119 external-priority patent/US8664265B2/en
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP2731603A1 publication Critical patent/EP2731603A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the field of the invention relates to stable oral dosage forms comprising spiro or dispiro 1 ,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues and processes for their preparation.
  • Malaria the most common parasitic disease of humans, remains a major health and economic burden in most tropical countries. Large areas of Central and South America, Hispaniola (Haiti and the Dominican Republic), Africa, the Middle East, the Indian subcontinent, Southeast Asia, and Oceania are considered as malaria-risk areas. It leads to a heavy toll of illness and death, especially amongst children and pregnant women.
  • the disease infects about 400 million people each year, and around two to three million people die from malaria every year.
  • malaria parasites that infect human: Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium malariae.
  • sporozoites When a mosquito sucks the blood of human, sporozoites are transfused into the human body together with saliva of the mosquito. The sporozoites enter into the hepatocytes, reproduce asexually and finally enter into the blood stream. The parasites continue to multiply inside the red blood cells, until they burst and release large number of merozoites. This process continues, destroying a significant number of blood cells and causing the characteristic paroxysm ("chills and fever") associated with the disease. In the red blood cells, some of the merozoites become male or female gametocytes. These gametocytes are ingested by the mosquito when it feeds on blood. The gametocytes fuse in the vector's gut; sporozoites are produced and are migrated to the vector's salivary glands.
  • the clinical symptoms of malaria are generally associated with the bursting of red blood cells causing an intense fever associated with chills that can leave the infected individual exhausted and bedridden. More severe symptoms associated with repeat infections and/or infection by Plasmodium falciparum include anaemia, severe headaches, convulsions, delirium and, in some instances, death.
  • Quinine an antimalarial compound that is extracted from the bark of cinchona tree, is one of the oldest and most effective drugs in existence. Chloroquine and mefloquine are the synthetic analogs of quinine developed in 1940's, which due to their effectiveness, ease of manufacture, and general lack of side effects, became the drugs of choice. The downside to quinine and its derivatives is that they are short-acting and have bitter taste. Further, they fail to prevent disease relapses and are also associated with side effects commonly known as "Chinchonism syndrome" characterized by nausea, vomiting, dizziness, vertigo and deafness. However, in recent years, with the emergence of drug- resistant strains of parasite and insecticide-resistant strains of vector, the treatment and/or control of malaria is becoming difficult with these conventional drugs.
  • the present invention relates to solid dosage forms of the various spiro or dispiro 1 ,2,4- trioxolanes antimalarial compounds disclosed in these patents/applications and are incorporated herein by reference.
  • Trioxolane derivatives possess excellent potency, efficacy against Plasmodium parasites, and a lower degree of neurotoxicity, in addition to their structural simplicity and ease of synthesis. Furthermore, these compounds have half-lives which are believed to permit short-term treatment regimens comparing favorably to other artemisinin-like drugs.
  • the therapeutic dose of trioxolane derivative may range between about 0.1-1000 mg/kg/day, in particular between about 1-100 mg/kg/day.
  • the foregoing dose may be administered as a single dose or may be divided into multiple doses.
  • a typical dosing schedule could be, for example, 2.0-1000 mg/kg weekly beginning 1-2 weeks prior to malaria exposure, continued up to 1-2 weeks post-exposure.
  • Monotherapy with artemisinin (natural or synthetic) class of drugs might cure the patients within 3 days, however perceiving the potential threat of the malarial parasite developing resistance towards otherwise very potent artemisinin class of drugs, WHO had strictly called for an immediate halt to the provision of single-drug artemisinin malaria pills.
  • Combination therapy in case of malaria retards the development of resistance, improve efficacy by lowering recrudescence rate, provides synergistic effect, and increase exposure of the parasite to the drugs.
  • Artemsinin based combinations are available in the market for a long time.
  • Artemether-lumafentrine was the first fixed dose antimalarial combination containing an artemisinin derivative and has been known since 1999. This combination has passed extensive safety and efficacy trials and has been approved by more than 70 regulatory agencies. Co-artem® is recommended by WHO as the first line treatment for uncomplicated malaria.
  • the dosage regimen of Co-artem® for an adult having body weight of more than 35 kg includes 6 doses over three days.
  • the first dose comprises four tablets initially, the second dose comprises four tablets after eight hours, the third to sixth doses comprise four tablets twice for another two days; making it a total of 24 tablets.
  • the dosage regimen of Coarsucam® for an adult having body weight of more than 36 kg or age above 14 years includes three doses over three days; each dose comprises two tablets; making it a total of six tablets.
  • the dosage regimen of Eurartesim® for an adult having body weight between 36 kg - 75 kg includes 3 doses over three days, each dose comprises of three tablets, making it a total of nine tablets.
  • a stable antimalarial oral solid dosage form comprising spiro or dispiro 1 ,2,4-trioxolanes can be prepared by controlling the water content below a certain critical limit. Further, the bitter taste can be masked by applying a film coating layer to the solid dosage form.
  • a stable solid oral dosage form that includes a therapeutically effe structural Formula I,
  • Ri and R2 are same or different and are selected from hydrogen, substituted or unsubstituted linear or branched alkyl, aryl, and alkaryl groups and substituted or unsubstituted alicyclic groups that are optionally interrupted by one or more oxygen, sulfur or nitrogen atoms, substituted or unsubstituted aromatic or heterocyclic groups that may be interrupted by one or more oxygen, sulfur or nitrogen atoms, a hydroxy group, and a halogen, and further providing that the spirocyclohexyl rings attaching Ri and R2 are optionally interrupted by one or more oxygen, sulfur, or nitrogen atoms; and one or more pharmaceutically acceptable excipients, wherein not more than 5% w/w total related substances are formed on storage at 40°C ⁇ 2°C and 75% ⁇ 5% relative humidity over a period of 6 months.
  • Embodiments of the solid oral dosage form may include one or more of the following features.
  • the dosage form may include one or more of other antimalarial drugs.
  • the other antimalarial drugs may include quinine, mefloquine, lumefantrine, sulfadoxine-pyrimethamine, dihydroartimisinin, piperaquine, chloroquine, amodiaquine, proguanil, atovaquone, chloroproguanil, dapsone, fosmidomycin, tetracycline, DB 289 (pafuramidine maleate), clindamycin, or their salts and derivatives thereof.
  • piperaquine, lumefantrine and DB 289 may be used.
  • a method of treatment of malaria includes administering a solid dosage form that includes a therapeutically effective amount of a compound of structural Formula I; and one or more pharmaceutically acceptable excipients, wherein not more than 5% w/w total related substances are formed on storage at 40°C ⁇ 2°C and 75% ⁇ 5% relative humidity over a period of 6 months.
  • a method of treatment of malaria includes administering a solid dosage form that includes a therapeutically effective amount of a compound of structural Formula I, formulated using a dry or non-aqueous process.
  • a stable solid oral dosage form wherein the dosage form includes a therapeutically effective amount of a compound of structural
  • Formula I at least one other antimalarial drug selected from lumefantrine, piperaquine, or DB 289; and one or more pharmaceutically acceptable excipients.
  • Embodiments of the oral dosage form may include one or more of the following features.
  • the water content of the dosage form may not be more than 6.5% w/w.
  • a stable oral solid dosage form comprising cis-adamantane-2-spiro-3'-8'-[[[(2'-amino-2'-methylpropyl) amino]carbonyl]- methyl]-r,2',4'-trioxaspiro[4.5]decane hydrogen maleate; piperaquine; and one or more pharmaceutically acceptable excipients.
  • a stable solid oral dosage form comprising; (a) cis-adamantane-2-spiro-3'-8'-[[[(2'-amino-2'- methylpropyl)amino]carbonyl]-methyl]-r,2',4'-trioxaspiro[4.5]decane hydrogen maleate (Active compound I);
  • the dosage form is prepared by a dry process.
  • a stable solid oral dosage form comprising;
  • the total drug content is within the range of from about 25% to about 85% w/w based on the total weight of the dosage form.
  • a stable solid oral dosage form comprising;
  • a stable solid oral dosage comprising;
  • a stable solid oral dosage of Active compound I and piperaquine wherein the dosage form has dissolution performance such that more than 70% w/w of the Active compound I dissolves within 45 minutes, in a pH 4.5 acetate buffer with 2% tween 80, in USP type II apparatus.
  • a stable solid oral dosage form comprising; (a) Active compound I and
  • a stable oral solid dosage form comprising Active compound I present in a dose range of about 100 to about 300 mg and piperaquine present in a dose range of about 700 mg to about 850 mg.
  • a stable solid oral dosage form comprising;
  • lubricant in an amount of from about 1% to about 5%; w/w based on the total weight of the dosage form.
  • a stable solid oral dosage form comprising;
  • a stable oral solid dosage comprising;
  • microcrystalline cellulose in an amount of from about 10% to about 40%; w/w based on the total weight of the dosage form.
  • a stable solid oral dosage form comprising Active compound I and microcrystalline cellulose in a weight ratio of about 1 : 1 to about 1 :5.
  • the pharmaceutically acceptable excipients may be selected from the group consisting of binders, diluents, glidants/lubricants, disintegrants, surfactants and coloring agents.
  • the solid dosage form may be in the form of a tablet, capsule, pellet, pill, granule or powder.
  • the dosage form is a tablet or a capsule. More particularly, the dosage form is a tablet.
  • a stable solid oral dosage form wherein the dosage form is processed and stored at a temperature below 27°C and relative humidity 50%.
  • the dosage form is formulated using a dry or non-aqueous process.
  • the nonaqueous process may include a non-aqueous granulating liquid selected from ethanol, isopropyl alcohol, acetone, or dichloromethane for preparing the binder solution.
  • the dry process may include direct compression or dry granulation. Dry granulation may be compaction or slugging. In particular, the dry granulation may be compaction for example, dry roller compaction.
  • a process for the preparation of a stable solid oral dosage form comprising the steps of; (a) blending Active compound I, piperaquine, and one or more intragranular excipients;
  • the tablet may be coated with layer(s) of one or more film forming polymers.
  • a method of treatment of malaria includes administering a stable oral solid dosage form comprising;
  • the dosage form is prepared by a dry process.
  • a stable solid oral dosage form comprising;
  • a method of treating malaria comprising administering a stable solid oral dosage form comprising;
  • the dosage form is administered once a day for three days.
  • stable refers to chemical stability of active compound in solid dosage forms against decomposition occurring during shelf life due to hydrolysis, wherein not more than 5% w/w total related substances are formed on storage at 40°C ⁇ 2°C and 75% ⁇ 5% relative humidity over a period of 6 months.
  • the present invention provides stable solid oral dosage forms of the active compound, by using excipients having low water content and manufactured using dry or non-aqueous formulation processes.
  • active compound includes spiro or dispiro 1,2,4- trioxolane compound of structural Formula I
  • Ri and R2 are same or different and are selected from hydrogen, substituted or unsubstituted linear or branched alkyl, aryl, and alkaryl groups and substituted or unsubstituted alicyclic groups that are optionally interrupted by one or more oxygen, sulfur or nitrogen atoms, substituted or unsubstituted aromatic or heterocyclic groups that may be interrupted by one or more oxygen, sulfur or nitrogen atoms, a hydroxy group, and a halogen, and further providing that the spirocyclohexyl rings attaching Ri and R2 are optionally interrupted by one or more oxygen, sulfur, or nitrogen atoms.
  • Rj is hydrogen, for example, compounds of structural Formula II.
  • Active compound includes one or more of the various spiro and dispiro trioxolane derivatives disclosed in U.S. Application No. 2004/0186168 and U.S. Patent Nos.
  • trioxolanes are relatively sterically hindered on at least one side of the trioxolane heterocycle which provides better in vivo activity, especially with respect to oral administration.
  • spiro and dispiro 1,2,4-trioxolanes derivatives possess excellent potency and efficacy against Plasmodium parasites, and a lower degree of neurotoxicity.
  • Active compound I herein means cis-adamantane-2-spiro-3'-8'-[[[(2'- amino-2'-methylpropyl)amino]carbonyl]-methyl]- 1 ',2',4'-trioxaspiro[4.5]decane hydrogen maleate.
  • the Active compound I may be present in an amount of from about 5% to about 25%, w/w based on the total dosage form.
  • Combination therapy is expected to retard the development of resistance, improve efficacy by lowering recrudescence rate, provide synergistic effect, and increase exposure of the parasite to the drugs.
  • Embodiments of the solid oral dosage of the present invention further include one or more of antimalarial drugs.
  • the antimalarial drugs may include quinine, mefloquine, lumefantrine, sulfadoxine-pyrimethamine, dihydroartimisinin, piperaquine, chloroquine, amodiaquine, proguanil, atovaquone, chloroproguanil, dapsone, fosmidomycin, tetracycline, DB 289 (pafuramidine maleate), clindamycin, or their salts and derivatives thereof.
  • piperaquine, lumefantrine and DB 289 may be used; however piperaquine remains the preferred one.
  • Selection of combination as an antimalarial therapy is based on certain attributes.
  • Synthetic artemisinin derivatives exhibit their action by their reaction with the iron in free heme molecules in the malaria parasite with the generation of free radicals leading to cellular destruction.
  • bisquinoline derivatives such as piperaquine interfere with the detoxification of haemin in the digestive vacuole of the parasite to non- toxic malaria pigment, so that haemin can generate free radicals and membrane damage follows.
  • the unrelated mode of action of the two drugs would provide improved therapy, and treatment against all stages of parasites including gametocytes.
  • synthetic artemisinin derivatives are very efficacious and highly potent, these would thereby treat the symptoms quickly, exhibiting fast recovery rates.
  • the combination of synthetic artemisinin derivatives and bisquinoline derivatives such as piperaquine provide a short duration of treatment.
  • Piperaquine is a bisquinoline compound that has antimalarial activity against both P. vivax wad P. falciparum, including strains of chloroquine resistant P. falciparum.
  • the tolerability, efficacy, pharmacokinetic profile, low cost and longer-acting piperaquine makes it a very perfect candidate for use in combination with short and rapidly acting
  • Piperaquine of the present invention includes piperaquine phosphate. Piperaquine may be present in an amount of from about 40% to about 80%, w/w based on the total dosage form.
  • the total drug content of the oral dosage forms of the present invention is within the range of about 25% to about 85%, and in particular does not exceed 85% w/w based on the total dosage form.
  • the oral dosage forms of the present invention comprise Active compound I and piperaquine in a weight ratio of about 1 : 1 to about 1 : 10.
  • the oral dosage forms of the present invention comprise Active compound I present in a dose range of about 100 mg to about 300 mg and piperaquine present in a dose range of about 700 mg to about 850 mg.
  • the oral dosage forms of the present invention comprise Active compound I present in a unit dose of 100 mg, 150 mg or 250 mg and piperaquine present in a unit dose of 750 mg.
  • the oral dosage forms of the present invention comprise Active compound I in a unit dose of about 100 mg and piperaquine present in a unit dose of about 750 mg.
  • the oral dosage forms of the present invention comprise Active compound I in a unit dose of about 150 mg and piperaquine present in a unit dose of about 750 mg
  • the oral dosage forms of the present invention comprise Active compound I in a unit dose of about 200 mg and piperaquine present in a unit dose of about 750 mg
  • the dosage regimen of the present invention includes administering a fixed dose combination of 150 mg Active compound I and 750 mg of piperaquine once a day for three days.
  • the dose of Active compound I herein means dose equivalent to Active compound I free base.
  • the dosage regimen of the present invention includes three doses over three days.
  • the first dose is administered immediately on diagnosis, the second dose about 24 hours after the first dose, and the third dose about 24 hours after the second dose.
  • the dosage regimen of the present invention is suitable for all patients aged from 12 to 65 years and thus eliminates the need for calculating dose based on individual weight parameters.
  • the dose is calculated with respect to the individual weight of the patient and in many cases the tablets are scored to adjust the dose.
  • the dosage regimen of this combination is surprisingly simple and effective both for patients and for prescribers.
  • Solid dosage form as used herein is selected from a group consisting of tablets or coated tablets, capsules, pellets, pills, granules and powders. A particularly suitable solid dosage form is that of tablets.
  • the stable solid oral dosage forms of the present invention may further comprise one or more pharmaceutically acceptable excipients, which include all physiologically inert excipients used in the art for the preparation of solid dosage forms. Examples include binders, diluents, glidants/lubricants, disintegrants, surfactants, coloring agents, and the like.
  • the excipients may be used either intragranularly or extragranularly, or both.
  • the weight ratio of active compound and excipients in the dosage forms may vary from about 1.5: 1 to about 1 :30.
  • binders include methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, gelatin, gum arabic, ethyl cellulose, polyvinyl alcohol, pullulan, agar, tragacanth and sodium alginate, or mixtures thereof.
  • diluents examples include cellulose powdered, microcrystalline cellulose, dextrates, dextrins, dextrose excipients, fructose, kaolin, lactitol, mannitol, sorbitol, sucrose, sugar compressible, and sugar confectioners, in particular microcrystalline cellulose.
  • the diluents may be present in an amount from about 10% to about 40% w/w based on the total weight of the dosage form. Further the weight ratio of Active compound I to microcrystalline cellulose may vary from about 1 : 1 to about 1 :5.
  • disintegrants examples include clays, celluloses, alginates, gums, cross-linked polymers (such as cross-linked polyvinylpyrrolidone and cross-linked sodium
  • the disintegrant may be present in an amount from about 1% to about 10% w/w based on the total weight of the dosage form.
  • lubricants or glidants include talc, magnesium stearate, calcium stearate, stearic acid, colloidal silicon dioxide, magnesium carbonate, magnesium oxide, calcium silicate, microcrystalline cellulose, mineral oil, waxes, glyceryl behenate, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, sodium laurylsulfate, sodium stearyl fumarate, and hydrogenated vegetable oils, sucrose esters of fatty acid, microcrystalline wax, yellow beeswax, white beeswax, in particular magnesium stearate.
  • the lubricant may be present in an amount from about 1% to about 5%, w/w based on the total weight of the dosage form.
  • surfactants include both non-ionic and ionic (cationic, anionic and zwitterionic) surfactants suitable for use in sweetener compositions. These include polyethoxylated fatty acids and its derivatives, for example polyethylene glycol 400 distearate, polyethylene glycol-20 dioleate, polyethylene glycol 4-150 mono dilaurate, polyethylene glycol— 20 glyceryl stearate; alcohol— oil transesterification products, for example polyethylene glycol-6 corn oil; polyglycerized fatty acids, for example polyglyceryl— 6 pentaoleate; propylene glycol fatty acid esters, for example propylene glycol monocaprylate; mono and diglycerides, for example glyceryl ricinoleate; sterol and sterol derivatives; sorbitan fatty acid esters and its derivatives, for example polyethylene glycol— 20 sorbitan monooleate, sorbitan monolaurate; polyethylene glycol alkyl ether
  • the coloring agents include any FDA approved colors for oral use.
  • the solid dosage forms may further be coated with one or more functional and/or non-functional layers comprising film-forming polymers, and other coating additives.
  • film-forming polymers include cellulose derivatives such as ethyl cellulose, hydroxypropyl methylcellulose, hydroxypropylcellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, partially hydrolyzed polyvinyl alcohol, cellulose acetate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate; waxes such as polyethylene glycol; and methacrylic acid polymers such as Eudragit® RL and RS.
  • commercially available coating compositions comprising film- forming polymers marketed under various trade names, such as Opadry®, may also be used for coating.
  • the coating additives comprise one or more of plasticizers, glidants or flow regulators, opacifiers and lubricants.
  • the pharmaceutical acceptable excipients and/or film forming polymers and coating additives may be selected to provide an immediate-release profile or a modified release profile.
  • Solid dosage forms of Active compound I may be prepared by densifying Active compound I and one or more excipients, and processing into solid dosage forms.
  • Densification may be carried out using any conventional method known in the art. In particular, granulation or extrusion-spheronization may be used.
  • stable oral tablets of Active compound I may be prepared by a process comprising the steps of blending Active compound I and intragranular portion of a diluent, lubricant, and disintegrant; passing the blend through a roller compactor to form a compact mass; reducing the compact mass into granules of suitable size; blending the granules with extragranular portion of a lubricant, disintegrant, and diluent in a double cone blender; and finally compressing into tablets using suitable tooling.
  • stable oral tablets of Active compound I may be prepared by a process comprising the steps of blending Active compound I and intragranular portion of a diluent, lubricant, and disintegrant; compressing the blend in a heavy tabletting press to form slugs; reducing the slugs into granules of suitable size; blending the granules with extragranular portion of a lubricant, disintegrant, and diluent in a double cone blender; and finally compressing into tablets using suitable tooling.
  • stable oral capsules of Active compound I may be prepared by a process comprising the steps of blending Active compound I and intragranular portion of a diluent, lubricant, and disintegrant; passing the blend through a roller compactor to form a compact mass; reducing the compact into granules of a suitable size; blending the granules with extragranular portion of a lubricant in a double cone blender; and finally filling into capsules of a suitable size.
  • stable oral capsules of Active compound I may be prepared by a process comprising the steps of blending Active compound I and intragranular portion of a diluent, lubricant, and disintegrant; compressing the blend in a heavy tabletting press to form slugs; reducing the slugs into granules of a suitable size; blending the granules with extragranular portion of lubricant in a double cone blender; and finally filling into capsules of a suitable size.
  • stable oral tablets of Active compound I may be prepared by a process comprising the steps of blending Active compound I, a diluent, a lubricant and a disintegrant; and directly compressing into tablets using suitable tooling.
  • stable oral capsules of Active compound I may be prepared by a process comprising the steps of blending Active compound I, a diluent, and a lubricant; and filling into capsules of a suitable size.
  • stable oral tablets of Active compound I may be prepared by a process comprising the steps of blending Active compound I and intragranular portion of a diluent, and disintegrant; wet granulating the blend with a non aqueous granulating fluid or a solution/dispersion of pharmaceutically acceptable excipients in the non-aqueous granulating fluid; drying and reducing the granules to a suitable size, blending the granules with extragranular portion of a lubricant, disintegrant and diluent in a double cone blender; and finally compressing into tablets using suitable tooling.
  • stable oral capsules of Active compound I may be prepared by a process comprising the steps of blending Active compound I and intragranular portion of diluent, and disintegrant; wet granulating the blend with a non aqueous granulating fluid or a solution/dispersion of pharmaceutically acceptable excipients in the non-aqueous granulating fluid; drying and reducing the granules to a suitable size; blending the granules with extragranular portion of lubricant in a double cone blender; and finally filling into capsules of a suitable size.
  • non-aqueous granulating fluid examples include organic solvents such as methanol, ethanol, isopropyl alcohol, dichloromethane, acetone, or mixtures thereof.
  • tablets prepared by any of the above described processes may further be coated with film- forming polymers and one or more coating additives, using techniques well known in the art such as spray coating in a conventional coating pan or a fluidized bed processor or dip coating. Alternatively, coating can also be performed using a hot melt technique.
  • the coating layers over the tablet may be applied as a solution/dispersion of coating components in a suitable solvent.
  • solvents used for preparing a solution/dispersion of the coating ingredients include methyl alcohol, ethyl alcohol, isopropyl alcohol, n-butyl alcohol, acetone, acetonitrile, chloroform, methylene chloride, water and the like, and mixtures thereof.
  • one or more of another antimalarial drug selected from piperaquine, lumefantrine, and DB 289 may be added in the blend comprising active compound, in any of the embodiments above.
  • the dosage form of the present invention is processed and stored at a temperature below 27°C and relative humidity 50%.
  • Active compound I and intragranular portion of microcrystalline cellulose were sieved through sieve BSS #44 and mixed together in a double cone blender to form a uniform blend.
  • step 2 To the blend of step 1, intragranular portion of sifted magnesium stearate was added and blended for about 5 minutes. 3. The blend of step 2 was compacted in a roller compactor and was sifted through sieve BSS #22 to form granules.
  • step 4 was compressed using suitable size punches to obtain compressed tablets.
  • Active compound I microcrystalline cellulose, croscarmellose sodium and magnesium stearate were sifted through sieve BSS #44.
  • Sifted Active compound I, microcrystalline cellulose, and croscarmellose sodium were mixed in a double cone blender for about 15 minutes to form a uniform blend.
  • step 3 To the blend of step 2, sifted magnesium stearate was added and mixed for about 5 minutes.
  • step 3 The blend obtained in step 3 was directly compressed using suitable size capsule shape punches to obtain compressed tablets.
  • Active compound I Piperaquine phosphate and intragranular portion of microcrystallme cellulose and crospovidone were sieved through sieve BSS # 44 and mixed together in a double cone blender to form a uniform blend.
  • step 2 To the blend of step 1, intragranular portion of sifted magnesium stearate was added and blended for about 5 minutes.
  • step 3 The blend of step 2 was compacted in a roller compactor and was sifted through sieve BSS # 18 to form granules.
  • step 5 Extragranular portion of magnesium stearate was sieved through sieve BSS # 44 and blended with the blend of step 4 in a double cone blender for about 5 minutes. 6. The blend of step 5 was compressed using suitable size punches to obtain compressed tablets. 7. The tablets as obtained from step 6 were coated with Opadry® using conventional coating techniques and weight built of up to 2.5% w/w.
  • the tablets prepared as per the Example 3 & 4 were subjected to stability studies at 40°C/RH 75% over a period of 3 months, as represented in Table 4.
  • Active compound I Piperaquine phosphate and intragranular portion of microcrystalline cellulose and crospovidone were sieved through sieve BSS # 44 and mixed together.
  • step 2 To the blend of step 1, intragranular portion of sifted magnesium stearate was added and blended for about 5 minutes.
  • step 3 The blend of step 2 was compacted and compacts were sifted through sieve BSS # 18 to form granules.
  • step 5 The blend of step 5 was compressed using suitable size punches to obtain compressed tablets.
  • Table 5 Percentage (% w/w) of In vitro drug release of Active compound I, from example 5, in USP II apparatus* (media: 2% tween 80 in water, 900ml, 75 rpm)
  • a Phase II, double blind, parallel group, randomized, dose finding study was performed to determine the safety and efficacy of three dose levels (50 mg, 100 mg and 200 mg) of Active compound I administered for three days in patients with uncomplicated P. falciparum malaria.
  • Preliminary data showed that the mean parasite clearance time for the patient on 50 mg was 52 hours, and all the 3 patients who were followed up for 28 days showed reappearance of parasites.
  • Patients receiving 100 mg had a parasite clearance time of 46.6 hours and 5 of total 6 patients showed reappearance of parasites.
  • Patients receiving 200 mg had a parasite clearance time of 30.4 hours and 4 out of 5 patients showed adequate clinical and parasitological response (ACPR) at day 28. Only 1 patient showed reappearance of parasites.
  • ACPR clinical and parasitological response
  • Piperaquine phosphate was chosen as a partner drug and a Phase I double blind, randomized, parallel group, placebo controlled study was conducted in young healthy male subjects to investigate the safety, tolerability and pharmacokinetic profile of Active compound I and piperaquine phosphate after co-administration of multiple oral doses.
  • the study comprised of three cohorts.
  • Cohort I received an oral daily dose of 100 mg of Active compound I and 750 mg of piperaquine phosphate
  • Cohort II received an oral daily dose of 200 mg of Active compound I and 750 mg of piperaquine phosphate
  • Cohort III received an oral daily dose of 200 mg of Active compound I and 1000 mg of piperaquine phosphate. All three doses were administered once daily for three days in each cohort. No drug related adverse event was observed up to dose levels of 200 mg Active compound I and 750 mg of piperaquine phosphate.
  • somnolence and vomiting were reported in dose level of 200 mg Active compound I and 1000 mg of piperaquine phosphate
  • R 0 Degree of accumulation calculated as (AUCo-24(Day 3)/AUCo-24 (Day 1))
  • a single-dose, two-treatment, parallel design study comparing the bioavailability of fixed dose combination tablets of Active compound I 150 mg + piperaquine phosphate 750 mg with co-administered Active compound I 150 mg and piperaquine phosphate 750 mg was conducted as an open label, balanced, randomized, single-dose, two-treatment, parallel design in 36 healthy, adult, human, male subjects under fasting conditions.
  • the pharmacokinetic parameters are presented in Tables 7 and 8. The results of this study suggested that the pharmacokinetics of Active compound I remained unaltered when administered in fixed-dose combination with piperaquine phosphate as compared to their co-administration as individual tablets.
  • Table 7 Geometric mean pharmacokinetic parameters of Active compound I (free base) following administration of fixed-dose combination (FDC) and co-pack formulations of Active compound I and piperaquine phosphate to young healthy male subjects.
  • Table 8 Geometric mean pharmacokinetic parameters of piperaquine following administration of fixed-dose combination (FDC) and co-pack formulations of Active compound I and piperaquine phosphate to young healthy male subjects.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP12743776.2A 2011-07-14 2012-07-13 Stable dosage forms of arterolane and piperaquine Withdrawn EP2731603A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/183,119 US8664265B2 (en) 2005-05-18 2011-07-14 Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials
IN2703DE2011 2011-09-19
IN2156DE2012 2012-07-12
PCT/IB2012/053614 WO2013008218A1 (en) 2011-07-14 2012-07-13 Stable dosage forms of arterolane and piperaquine

Publications (1)

Publication Number Publication Date
EP2731603A1 true EP2731603A1 (en) 2014-05-21

Family

ID=47505579

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12743776.2A Withdrawn EP2731603A1 (en) 2011-07-14 2012-07-13 Stable dosage forms of arterolane and piperaquine

Country Status (10)

Country Link
EP (1) EP2731603A1 (ko)
JP (1) JP2014522856A (ko)
KR (1) KR20140053169A (ko)
CN (1) CN103930107A (ko)
AP (1) AP2014007413A0 (ko)
AU (1) AU2012282077A1 (ko)
CA (1) CA2850089A1 (ko)
EA (1) EA201490233A8 (ko)
MX (1) MX2014000463A (ko)
WO (1) WO2013008218A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2015008748A0 (en) 2013-02-28 2015-09-30 Sun Pharmaceutical Ind Ltd Stable dispersible formulation of arterolane maleate and piperaquine and process of preparation thereof
KR101698003B1 (ko) * 2016-06-20 2017-01-19 여오영 퀴닌 염 현탁액을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
BR112020011506A2 (pt) * 2017-12-12 2020-11-17 Intervet International B.V. composições farmacêuticas de isoxazolina implantáveis e usos das mesmas
WO2022034553A1 (en) * 2020-08-14 2022-02-17 Sun Pharmaceutical Industries Limited Fixed dose combination drug for the treatment of malaria

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486199B1 (en) 2001-06-21 2002-11-26 Medicines For Malaria Venture Mmv International Centre Cointrin Spiro and dispiro 1,2,4-trioxolane antimalarials
US6825230B2 (en) 2002-06-21 2004-11-30 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trixolane antimalarials
US6906205B2 (en) 2002-06-21 2005-06-14 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
ES2615458T3 (es) * 2005-05-18 2017-06-07 Sun Pharmaceutical Industries Limited Formas de dosificación estables de antimaláricos de espiro y dispiro 1,2,4 trioxolano
BRPI0711585A2 (pt) * 2006-05-17 2011-11-16 Ranbaxy Lab Ltd terapia antimalárica

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013008218A1 *

Also Published As

Publication number Publication date
AU2012282077A1 (en) 2014-01-30
CA2850089A1 (en) 2013-01-17
JP2014522856A (ja) 2014-09-08
KR20140053169A (ko) 2014-05-07
CN103930107A (zh) 2014-07-16
EA201490233A1 (ru) 2014-07-30
EA201490233A8 (ru) 2015-01-30
WO2013008218A1 (en) 2013-01-17
AP3777A (ko) 2016-08-31
AP2014007413A0 (en) 2014-02-28
MX2014000463A (es) 2014-07-09

Similar Documents

Publication Publication Date Title
US8664265B2 (en) Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials
JP5752132B2 (ja) 苦味を呈する薬物を含有する顆粒および口腔内崩壊錠
RU2328274C2 (ru) Препарат ламотриджин с контролируемым высвобождением
KR101378973B1 (ko) 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
JP6288158B2 (ja) 品質が向上した経口製剤
EP0749308B1 (en) Film coated tablet of paracetamol and domperidone
AU2012340759A1 (en) Pharmaceutical formulations
KR101828630B1 (ko) 구강 내 붕괴 정제
EP2731603A1 (en) Stable dosage forms of arterolane and piperaquine
WO2010023690A2 (en) Prolonged release formulation of amisulpride
EP2698150A1 (en) Oral solid preparation of compound antituberculosis drug and preparation method thereof
WO2005023304A2 (en) Antimalarial compositions and manufacturing process thereof
KR20140081826A (ko) 서방성 제제
KR102127625B1 (ko) 하이드로모르폰염산염 함유의 경구용 서방성 의약 조성물
CN112955146A (zh) 包含抗肿瘤剂的医药组合物
EP3496719B1 (en) A multi-class anti-retroviral composition
AU2020286220B2 (en) An orally disintegrating pharmacutical composition comprising nefopam and process for preparing the same
WO2007017646A2 (en) Anti-malarial composition comprising artesunate and lumefantrine
MX2014007635A (es) Composicion farmaceutica no enterica que comprende crofelemer.
OA16845A (en) Stable dosage forms of arterolane and piperaquine
WO2014132226A1 (en) Stable dispersible formulation of arterolane maleate and piperaquine and process of preparation thereof
WO2022074681A1 (en) Pharmaceutical compositions with enhanced blend uniformity and content uniformity
KR100212960B1 (ko) 경구용 복합제제
KR20180002437A (ko) 독실아민 및 피리독신을 포함하는 약제학적 복합 제제

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ARORA, VINOD, KUMAR

Inventor name: BHATTACHARYYA, SANJUKTA

Inventor name: TYAGI, PUNEET

Inventor name: BALAJI, ANNAMDEVARA

Inventor name: TREHAN, ANUPAM

Inventor name: ENOSE, ARNO, APPAVOO

Inventor name: ROY, ARJUN

Inventor name: MADAN, SUMIT

Inventor name: MADAN, HARISH, KUMAR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1198127

Country of ref document: HK

17Q First examination report despatched

Effective date: 20160804

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161215

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1198127

Country of ref document: HK